Congress should use health reform to ban "pay-for-delay" deals

01/14/2010 | Washington Post, The

Lawmakers should include a provision in the health reform bill that would prevent brand-name drugmakers from entering into "pay-for-delay" deals with generic drug firms as a way to maintain the market exclusivity of their products, according to this Washington Post editorial. The practice forces government health insurance programs to pay billions of dollars for expensive treatments and consumers to lose an average of $3.5 billion annually in possible savings, the editorial adds.

View Full Article in:

Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ